The Amyloidogenesis Problem
Human amylin (also called islet amyloid polypeptide, IAPP) has a problem: at concentrations above physiological levels, it forms amyloid fibrils. This is not a research inconvenience — amylin fibrils are the pathological finding in type 2 diabetic pancreatic tissue. Using native human amylin as a research peptide is nearly impossible because of aggregation during handling.
Pramlintide solves this through targeted amino acid substitutions. The research-grade peptide is available as Pramlintide 5mg.
The Rat-Sequence Inspiration
Rat amylin does not form fibrils. Comparing rat and human amylin sequences reveals three key differences at positions 25, 28, and 29 — positions that happen to be in the aggregation-prone region of the peptide. In rat amylin, these positions are prolines; in human amylin, they are alanine and serines.
Pramlintide swaps the human residues for the rat prolines:
- Position 25: Ala → Pro
- Position 28: Ser → Pro
- Position 29: Ser → Pro
The substitutions disrupt the beta-sheet architecture required for fibril formation while preserving receptor binding.
Amylin Receptor Pharmacology
Amylin receptors are not standalone GPCRs — they are heterodimeric complexes of the calcitonin receptor (CALCR) with receptor activity-modifying proteins (RAMPs):
- AMY1 receptor: CALCR + RAMP1
- AMY2 receptor: CALCR + RAMP2
- AMY3 receptor: CALCR + RAMP3
Pramlintide binds all three complexes. Downstream signaling includes:
- Gastric emptying delay — slowing nutrient delivery
- Glucagon suppression — reducing hepatic glucose output
- Appetite suppression — hypothalamic action
Pramlintide vs Cagrilintide in Research
Both target amylin receptors:
| Property | Pramlintide | Cagrilintide |
|---|---|---|
| Half-life | 48 min | ~7 days |
| Dosing | Mealtime (TID) | Weekly |
| Modification | Proline substitutions | C20 fatty acid + substitutions |
| Research role | Acute pharmacology | Long-acting protocol research |
The short half-life of pramlintide makes it suitable for mealtime-aligned research and acute dose-response studies. Cagrilintide is the long-acting research tool for sustained amylin receptor engagement.
Combined Research Context
Amylin receptor agonists are commonly studied alongside GLP-1R agonists because the pathways are non-overlapping — the CagriSema combination (cagrilintide + semaglutide) is the modern example. Pramlintide + short-acting GLP-1R research is the equivalent acute pharmacology setup.
Handling
Standard lyophilized peptide handling applies. >98% HPLC purity. See Pramlintide 5mg for the research vial.